Clay Seigall could very well be considered a miracle worker. The CEO of Seattle Genetics specializes in solutions to diseases that lead to the death of the patient, and have not seen new drugs that help the patients’ mortality in decades. One major such disease is cancer, which Seigall is working on developing new drugs for. He believes that chemotherapy is on its way out. He’s not wrong to be optimistic – he developed the first FDA-approved antibody drug and more than 20 other drugs.
Seigall’s interest in treating cancer began when one of his family members almost died from anemia caused by chemotherapy. He knew there had to be a better way, so he went looking for one. Quoting Francis Galton, Charles Darwin’s cousin, he says that intellect is not the determiner of ability. He believes his success comes from his passion to succeed, and he believes that anyone can succeed if they work hard enough.
It is evident that Clay Seigall has worked hard in his life just from hearing a little bit about him. He earned a Ph.D. in genetics from The George Washington University and a Bachelor of Science in Zoology from the University of Maryland. Since then, he has earned positions on multiple advisory boards – Alder Biopharmaceutical’s Board of Directors, Mirna Therapeutic’s board, and the Fred Hutchinson Cancer Research Center’s Board of Governors. He was awarded the Entrepreneur of the Year Award by Pacific Northwest Ernst & Young in 2012, and the Alumnus of the Year Award for Computer, Math and Natural Sciences in 2013 by the University of Maryland.
Seigall was a member of Bristol-Meyers Squibb, a pharmaceutical research institute, from 1991 through 1997, and a member of the National Institutes of Health from 1988 to 1991. , Currently, he is a member of MedImmune, a company that develops medicines for unmet medical needs, Curagen Corporation, a pharmaceutical corporation for the development of medicines for the treatment of cancer, and PDL BioPharma, a biotechnology-related intellectual property asset management company.